Skip to main content
SpringerLink
Log in

Lobular Carcinoma In Situ

  • Chapter
Breast Disease

  • 2068 Accesses

Abstract

Lobular carcinoma in situ (LCIS) is a high-risk indicator lesion for and a non-obligate precursor of the development of invasive breast carcinoma. Loss of E-cadherin is the hallmark pathological feature of lobular entities. Effective clinical management of LCIS requires good communication between the radiologist, surgeon, pathologist, and medical oncologist and entails surgical excision, subsequent surveillance, and systemic and surgical strategies to reduce the risk of future invasive cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.

    Article  CAS  PubMed  Google Scholar 

  3. Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. 2007;31(5):717–23.

    Article  PubMed  Google Scholar 

  4. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol. 2001;176(5):1255–9.

    Article  CAS  PubMed  Google Scholar 

  5. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14(4):1008–11.

    Article  PubMed  Google Scholar 

  6. Degnim AC, King TA. Surgical management of high-risk breast lesions. Surg Clin North Am. 2013;93(2):329–40.

    Article  PubMed  Google Scholar 

  7. Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol. 1991;157(2):257–65.

    Article  CAS  PubMed  Google Scholar 

  8. Frykberg ER. Lobular carcinoma in situ of the breast. Breast J. 1999;5(5):296–303.

    Article  PubMed  Google Scholar 

  9. Page DL, Kidd Jr TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.

    Article  CAS  PubMed  Google Scholar 

  10. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100(2):238–44.

    Article  PubMed  Google Scholar 

  11. Abdel-Fatah TM, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.

    Article  PubMed  Google Scholar 

  12. Dabbs DJ, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.

    Article  PubMed  Google Scholar 

  13. Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002;15(10):1044–50.

    Article  PubMed  Google Scholar 

  15. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol. 2008;32(11):1721–6.

    Article  PubMed  Google Scholar 

  16. Hatzfeld M. The p120 family of cell adhesion molecules. Eur J Cell Biol. 2005;84(2–3):205–14.

    Article  CAS  PubMed  Google Scholar 

  17. Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004;23(48):7947–56.

    Article  CAS  PubMed  Google Scholar 

  18. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, et al. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24(2):209–31.

    Article  CAS  PubMed  Google Scholar 

  19. Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol. 2010;34(10):1472–9.

    Article  PubMed  Google Scholar 

  20. Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol. 1995;48(2):M74–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121(3):575–89.

    Article  CAS  PubMed  Google Scholar 

  22. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12(22):6652–62.

    Article  CAS  PubMed  Google Scholar 

  23. Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215(3):231–44.

    Article  CAS  PubMed  Google Scholar 

  24. Corben AD, Edelweiss M, Brogi E. Challenges in the interpretation of breast core biopsies. Breast J. 2010;16 Suppl 1:S5–9.

    Article  PubMed  Google Scholar 

  25. Houssami N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–95.

    Article  PubMed  Google Scholar 

  26. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy–clinical significance. Cancer. 2004;101(2):242–50.

    Article  PubMed  Google Scholar 

  27. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–a review. Eur J Surg Oncol. 2011;37(4):279–89.

    Article  CAS  PubMed  Google Scholar 

  28. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62(3):197–210.

    Article  CAS  PubMed  Google Scholar 

  29. Ciocca RM, Li T, Freedman GM, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 2008;15(8):2263–71.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20(10):3240–6.

    Article  PubMed  Google Scholar 

  31. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748.

    Google Scholar 

  32. Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol. 2011;18(11):3110–6.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, et al. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg. 2014;72 Suppl 1:S48–52.

    PubMed  Google Scholar 

  34. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  PubMed  Google Scholar 

  35. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.

    Article  CAS  PubMed  Google Scholar 

  36. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.

    Article  CAS  Google Scholar 

  37. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, Magee-Womens Hospital, University of Pittsburgh Medical Center, 300 Halket Street, Suite 2601, Pittsburgh, PA, 15213, USA

    Priscilla McAuliffe MD, PhD, FACS

  2. Magee-Women’s Surgical Associates, Bethel Park, PA, USA

    Priscilla McAuliffe MD, PhD, FACS

Authors
  1. Priscilla McAuliffe MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priscilla McAuliffe MD, PhD, FACS .

Editor information

Editors and Affiliations

  1. Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Institute of Oncology, Istanbul University, Istanbul, Turkey

    Abdullah İğci

  3. Magee-Womens Hospital of UPMC, Pittsburg, California, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

McAuliffe, P. (2016). Lobular Carcinoma In Situ. In: Aydiner, A., İğci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-22843-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22843-3_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22842-6

  • Online ISBN: 978-3-319-22843-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation